De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients

Fu, OY; Li, CL; Chen, CC; Shen, YC; Moi, SH; Luo, CW; Xia, WY; Wang, YN; Lee, HH; Wang, LH; Wang, SC; Pan, MR; Hou, MF; Hung, MC

Fu, OY; Hou, MF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Surg, Div Breast Oncol & Surg, Kaohsiung 80756, Taiwan.;Wang, SC; Hung, MC (通讯作者)，China Med Univ, Res Ctr Canc Biol, Taichung 40402, Taiwan.;Pan, MR (通讯作者)，Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung 80756, Taiwan.

AMERICAN JOURNAL OF CANCER RESEARCH, 2022; 12 (1): 123

Abstract

The atezolizumab (Tecentriq), a humanized antibody against human programmed death ligand 1 (PD-L1), combined with nab-paclitaxel was granted with acce......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索